Milestone Pharmaceuticals Inc. Stock Price

NasdaqGS:MIST Community·US$184.1m Market Cap

0 Narratives written by author
0 Comments on narratives written by author
21 Fair Values set on narratives written by author

Create a narrative

MIST Share Price Performance

US$1.92

0.48 (33.33%)

US$1.92

0.48 (33.33%)

US$1.92

Sat, 1 Nov 25

Share PriceUS$1.92

MIST Community Narratives

There are no narratives available yet.

Create a narrative

There are no community narratives available.

Snowflake Analysis

Slight risk and slightly overvalued.

4 Risks

2 Rewards

View Full Analysis

Milestone Pharmaceuticals Inc. Key Details

Last Reported Earnings

Jun 30, 2025

Next Reporting Earnings

n/a

: -0.57
: 0%
: 0%
: -311.3%

View Full Analysis

About MIST

Founded: 2003
Employees: 33
CEO: Joseph Oliveto
WebsiteView website: www.milestonepharma.com

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company’s lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.